Primary Sclerosing Cholangitis: Competitive Landscape

This reports provides a data-driven overview of the current and future competitive landscape in Primary Sclerosing Cholangitis therapeutics.

• In 2024, more than 17,000 diagnosed incident cases of PSC are anticipated in the 16 countries covered in GlobalData's epidemiology forecast for PSC.
• The treatment regimen for PSC primarily consists of ursodeoxycholic acid as the only disease-modifying therapy, supplemented by immunosuppressants and antibiotics.
• The PSC pipeline lacks assets in the pre-registration and Phase III development stages. There are 11 drugs in Phase II.
• In the last 10 years, 102 clinical trials have been carried out for PSC. The US is emerging as the key country for conducting PSC trials.
• Acquisitions dominated the deal landscape in North America.

Scope

GlobalData's Primary Sclerosing Cholangitis: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Primary Sclerosing Cholangitis market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Primary Sclerosing Cholangitis market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.